... San Antonio Breast Cancer Symposium 2023. Zanidatamab is a bispecific ... Some study authors declared affiliations with biotech, pharmaceutical, and/or ...
News
- Zanidatamab Combo Shows Activity in Heavily Pretreated, HR+, HER2+ Breast Cancer
- Less-Frequent Surveillance Mammo Feasible in Older Breast Cancer Survivors
... Health Sciences Center San Antonio, who was not involved with the study. ... Biotechnology, TerSera, and Menarini. Primary Source. San Antonio Breast ...
- Ford Fund, Nebraska Mobility Provider To Bridge Transportation Gaps In Detroit Healthcare
... Biotech|. Share This Story, Choose Your Platform! FacebookTwitterReddit ... Grand Rapids Fintech Provider Purchased By San Antonio Services Company ...
- Dato-DXd Deemed New Treatment Option for HR+, HER2- Advanced Breast Cancer
... San Antonio Breast Cancer Symposium 2023. Researchers found that Dato ... Some study authors declared affiliations with biotech, pharmaceutical, and/or ...
- Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast ...
... San Antonio Breast Cancer Symposium (SABCS). Information on the ... Intensity Therapeutics is a late-stage biotechnology company that applies novel ...